# Zymeworks Presents Phase 1 ZW191 Activity in Resistant Ovarian Cancer

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/40303
Published: 2026-10-24T20:18:17.000Z
Updated: 2026-10-24T20:18:17.000Z
Section: Business

> The heavily pretreated study population had platinum-resistant disease. The response-rate analysis focused on high-grade serous ovarian cancer.

Zymeworks Inc. presented Phase 1 dose-optimization data for ZW191 on Oct. 24, showing anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer; the drug targets folate receptor alpha (FRα).

ZW191 is an investigational antibody-drug conjugate. The response-rate analysis focused on high-grade serous ovarian cancer.